{"aliases":[{"type":"USBrandName","name":"Keytruda"},{"type":"Synonym","name":"pembrolizumab biosimilar RPH-075"},{"type":"Synonym","name":"pembrolizumab biosimilar SB27"},{"type":"CodeName","name":"RPH-075"},{"type":"Synonym","name":"anti-PD-1 monoclonal antibody MK-3475"},{"type":"Synonym","name":"immunoglobulin G4, anti-(human programmed cell death 1)"},{"type":"Synonym","name":"humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide"},{"type":"CodeName","name":"MK-3475"},{"type":"CodeName","name":"SCH 900475"},{"type":"ObsoleteName","name":"lambrolizumab"},{"type":"Synonym","name":"pembrolizumab biosimilar MB12"},{"type":"CASRegistryName","name":"1374853-91-4"},{"type":"ChemicalStructureName","name":"immunoglobulin G4, anti-(human programmed cell death 1); humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide"},{"type":"Synonym","name":"pembrolizumab biosimilar BCD-201"},{"type":"Synonym","name":"pembrolizumab biosimilar Q"},{"type":"CodeName","name":"BCD-201"},{"type":"Synonym","name":"pembrolizumab biosimilar QL2107"},{"type":"CodeName","name":"QL2107"}],"definition":{"html":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","text":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab","text":"Pembrolizumab"},"nciConceptId":"C106432","nciConceptName":"Pembrolizumab","termId":695789,"name":"pembrolizumab","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pembrolizumab"}